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Trigeminal-mediated headshaking in horses: 
prevalence, impact, and management strategies
Veronica Roberts
Bristol Vet School, Faculty of Health 
Sciences, University of Bristol, 
Langford, North Somerset BS40 5HB, 
UK
Abstract: Trigeminal-mediated headshaking is a little-understood neuropathic facial pain con-
dition of the horse. The condition may affect around 1% of the equine population to a degree of 
severity sufficient to require veterinary attention. As a pain condition, this represents a significant 
welfare issue. Horses are usually more severely affected at exercise which can leave them unable 
to perform, or even dangerous to ride and handle. With little known about the condition and 
variable response to treatments, severely affected horses are often euthanized. This review article 
considers the literature on trigeminal-mediated headshaking, focusing on what is known, and 
indeed not known, about the prevalence of the condition and its impact. The current published 
management options are considered, along with their challenges and limitations.
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Introduction
Occasional shaking of the head is a normal equine behavior. However, where the 
headshaking is any or all of frequent, violent, accompanied by flicks or jerks of the 
head, accompanied by signs of nasal irritation (such as snorting, sneezing, rubbing 
the nose, striking the nose), accompanied by signs of distress, or affects riding or 
handling the horse, then a pathological process must be considered.1 Conditions which 
can cause headshaking may include ear mite infestation, otitis interna, cranial nerve 
dysfunction, cervical injury, ocular disease, guttural pouch mycosis, dental periapi-
cal osteitis,2 protozoal myeloencephalitis,3 and sinusitis4 as well as a behavioral or 
rider issue.1 However, where shaking was such that referral veterinary advice was 
required, there was a 98% chance that no physical cause could be determined, lead-
ing to a diagnosis of idiopathic headshaking.2 As knowledge of this condition has 
developed, it is likely that most of these horses were suffering what is now termed 
trigeminal-mediated headshaking.1
Trigeminal-mediated headshaking appears to be an acquired disorder of the horse. 
Clinical signs are usually of predominantly vertical headshaking, which may be violent.1 
These movements are often accompanied by sharp vertical flicks and signs of nasal 
irritation.2 Typically, signs are worst at exercise,2,5,6 with only some horses being affected 
at rest also. Seasonality of clinical signs is usually reported in ~60% of headshaking 
horses, with the majority of these being spring/summer affected,5,7 although a more 
recent study found that owner’s reported horses were only completely free of signs 
seasonally in 25% cases (unpublished data). Even in nonseasonally affected horses, 
signs may vary with an apparent correlation to weather conditions.2,5,7
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The clinical signs of trigeminal-mediated headshaking 
are consistent with neuropathic pain of the trigeminal nerve. 
Although this was suspected even in the 19th century,8,9 there 
have been many other theories, with trigeminal involvement 
being only recently confirmed.10,11 These studies demon-
strated that the infraorbital branch of the trigeminal nerve 
of affected horses was sensitized, with a lower threshold for 
activation than unaffected horses. Somatosensory-evoked 
potentials were recorded under general anesthesia. These 
determined the threshold for activation for control horses 
to be >10 mA, but <5 mA for affected horses. There were 
no differences in the neurophysiological characteristics of 
the action potentials. Additionally, there were no differ-
ences between left and right sides, consistent with bilateral 
involvement of the trigeminal nerve. One seasonally affected 
horse was tested out of season and returned normal threshold 
activations, but was not tested when showing clinical signs, to 
see if then, threshold was abnormal. Should clinical signs be 
shown to change as threshold changes, then not only would 
that confirm causation but also suggest a potentially reversible 
condition. Further work is required in this area.
The reason for the sensitization of the trigeminal nerve 
remains unknown. While herpes virus is involved in the 
pathogenesis of some human neuropathic pain syndromes, 
the virus was not involved in the pathogenesis of trigeminal-
mediated headshaking.12 While trigeminal nerve root demy-
elination is the most frequent cause of trigeminal neuralgia, 
a neuropathic facial pain syndrome in people,13 no histo-
pathological abnormality of the nerve has been discovered.14 
Despite the apparent clinical similarities between trigeminal 
neuralgia and trigeminal-mediated headshaking, this result 
was not inconsistent with signs as human trigeminal neuralgia 
sufferers are usually unilaterally affected and would have 
abnormal conduction patterns.13 It can be considered to be 
a potentially positive result, as this condition would be less 
likely to be reversible. The results of these studies suggest a 
functional, rather than structural abnormality of the nerve, 
leading to the potential for developing a treatment which 
reverses the functional abnormality.
This summarizes the limited current knowledge of the 
causes and mechanisms of trigeminal-mediated headshak-
ing. Advances in treatment for trigeminal-mediated head-
shaking will remain limited until more is understood of the 
etiopathogenesis of the condition. There may be more than 
one cause with the same clinical manifestation, leading to 
different response rates to treatment. It is recognized in 
human medicine that response to treatment for neuropathic 
pain varies among individuals, even with the same diagno-
sis.32 Therefore, even if all trigeminal-mediated headshakers 
have the same underlying condition, response to the same 
treatment may vary.
It is against this challenging background that this article 
considers the prevalence, impact, and current management 
strategies for trigeminal-mediated headshaking. There 
is a need for further research into this condition to allow 
progression in treatment and even prevention. Establishing 
prevalence and welfare and economic impacts contributes to 
determining research priority for this condition, as does an 
understanding of the limited success of current treatments. 
This review considers and consolidates the current literature 
in these areas.
Prevalence
Knowledge of the prevalence of headshaking in the world-
wide population is fundamental to understanding the scale 
of the welfare issue that is trigeminal-mediated headshaking. 
While there are reports of horses with signs consistent with 
trigeminal-mediated headshaking from many developed 
countries, only the UK horse population has been used for 
prevalence studies. There may be a complex interaction with 
environment in this acquired condition of unknown etiology. 
For this reason, further information as to whether there is a 
difference in prevalence between countries, and in particular 
between developed and developing countries, would be of 
interest.
The prevalence of headshaking in the UK equine popula-
tion was first reported by Slater33 in 2013 as part of a general 
equine health survey. The prevalence of horses reported to 
have shaken their heads on a particular day of the year was 
reported to be between 1% and 1.5%. A dedicated study into 
the prevalence of headshaking in the UK equine population 
was published in 2018.15 Owners reported that 4.6% of their 
horses had shaken their heads in the last year, with 6.2% at 
any time point since ownership was considered. However, 
veterinary advice was required in only 30% of these horses. 
This suggests that medically significant headshaking can 
be expected to affect some 2% of UK horses. Assuming an 
approximate UK horse population of about one million31 
then some 20,000 of those horses could be suffering from 
significant neuropathic facial pain.
The study by Ross et al15 did not identify an association of 
sex or breed but median age was 12 years. There are further 
studies considering signalment. From this, it appears that the 
condition usually affects the adult horses first in the prime 
of their lives, with median ages of onset varying from 67 to 
10 years.16 Geldings appear to be overrepresented, compris-
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ing 63%7 to 71.5%5 cases. All breeds appear susceptible7 
(V Roberts, University of Bristol, personal communication, 
June, 2018). There are no longitudinal studies following 
disease progression, although there is a suggestion that some 
5% of horses may enter spontaneous long-term remission.5
While trigeminal neuropathy is recognized in small ani-
mals, there appears to be limited clinical overlap with trigem-
inal-mediated headshaking. To the author’s knowledge, there 
are only isolated anecdotal reports of clinical signs consistent 
with trigeminal-mediated headshaking, without investigation, 
in zebra and donkeys (V Roberts, personal communication, 
June, 2012). There may be potential to explore why horses 
might be affected but other Equidae not or rarely so, as this 
could potentially give some information as to etiology.
Impact
Impact encompasses morbidity, mortality, and economic 
burden.34 For trigeminal-mediated headshaking, this requires 
consideration of welfare and economic effects of the condi-
tion on the individual horse, the individual owner, and the 
equine industry as a whole. The potential for translational 
research should also be considered.
Horses suffering trigeminal-mediated headshaking are 
considered to have a neuropathic facial pain condition, and 
presence of pain has a negative impact on welfare. The degree 
of this negative impact can arguably be assumed to correlate 
with the severity of pain. Human patients with neuropathic 
pain may report signs varying from tingling up to unbearable 
electric shock-like pain, with quality of life significantly 
reduced with increasing pain.17 Severity of clinical signs in 
horses are likely to be our best indicator of severity of pain 
and severity of headshaking signs commonly vary between 
and within individuals. A variety of grading systems have 
been used to quantify severity of headshaking signs.6,18,19 The 
system used by Talbot focuses mostly on the effect of signs on 
the horse’s behavior, that by Roberts on the utility of the horse 
to the owner, and that by Newton is a combination (Table 1). 
An agreed methodology could be useful for more accurate 
monitoring of disease progression, treatment efficacy, and 
comparison of published studies,1 although incorporating 
both a horse and owner perspective may be of use. It could 
be inferred that disease of a severity such that horses meet 
grade 1/5 on Newton’s scale, 1/3 on Talbot’s scale, and 1/3 on 
Roberts’ scale has minimal impact on welfare and utility to the 
owner, and therefore minimal economic impact to the equine 
industry. Significant welfare and economic impact could be 
expected at the higher grades, with horses being retired or even 
euthanized if they cannot perform in their intended discipline. 
Of note are horses which would be classified as 3/3 on Rob-
erts’ scale. These horses suffer even at rest and so can have 
no respite. For these horses, even retirement is not an option, 
which may leave only euthanasia if treatment options fail.
There is at present no data considering the proportions 
of affected horses meeting each grading classification. These 
data would allow us to better assess scale of impact, by 
calculating the proportion of horses with significant welfare 
compromise, those retired and euthanized and from that, the 
cost of wastage to the equine industry.
There is potential for translational research, with clini-
cal similarities being present between trigeminal-mediated 
headshakers and people suffering neuropathic pain. This 
potential may, however, be limited, as there does not appear 
to be an exact parallel condition between people and horses. 
Trigeminal neuralgia is a neuropathic facial pain condition 
Table 1 Grading systems
Grading system Scale Classification
Newton and Knottenbelt 20006 1 intermittent and mild clinical signs. Facial muscle twitching. Rideable
2 Moderate clinical signs. Definable conditions under which they occur/develop. 
Rideable with some difficulty
3 Rideable but unpleasant ride, difficult to control
4 Unrideable, uncontrollable
5 Dangerous with bizarre behavior patterns
Talbot et al 201318 0 No headshaking
1 Mild signs at exercise
2 Obvious signs at exercise but no striking or behavioral changes
3 Most severe, with severe signs including behavioral changes and refusal to move
Roberts et al 201419 0 No signs of headshaking
1 Mild headshaking, insufficient as to interfere with ridden exercise
2 Headshaking at exercise of a severity sufficient as to make ridden exercise 
dangerous or impossible
3 Headshaking even at rest





in people, usually sudden in onset in late middle age and 
affecting a greater proportion of women.20 Sufferers usually 
report repeated paroxysms of unilateral facial pain, varying 
from tingling, through “pins and needles” to unbearable 
electric-shock pain. Episodes may be triggered by certain 
actions, such as light touch to the face. Causes of trigeminal 
neuralgia can be considered to fall into five categories, with 
the greatest proportion of cases being a result of unilateral 
focal demyelination at the trigeminal nerve root.13 There 
are obvious clinical differences with trigeminal-mediated 
headshakers, where geldings are more commonly affected 
and signs are bilateral. These differences were supported 
by one of the researchers working with this author,14 where 
no demyelination was identified at the trigeminal nerve 
root of trigeminal-mediated headshakers. Another cause 
of trigeminal neuralgia in people and of postherpetic neu-
ralgia is latent infection of herpes virus in the trigeminal 
ganglia. However, no evidence for an association with 
latent equine herpes virus-1 has been identified in horses.12 
A small amount of work has also been published on the use 
of electroacupuncture in horses presumed to be trigeminal-
mediated headshakers.21 There has been more extensive 
recent work in trigeminal-mediated headshakers, into the 
use of neuromodulation22 and (Roberts et al, unpublished 
data) using percutaneous electrical nerve stimulation which 
is used for the management of neuropathic pain in people. 
Very little is known about neuromodulation, and there is 
potential to expand this work using horses to improve our 
knowledge, which could impact on the management of neu-
ropathic pain in people. Otherwise, determining the etiology 
of trigeminal-mediated headshaking may open more doors 
for translational research.
Management strategies
With trigeminal-mediated headshaking neither the pathol-
ogy nor the cause of the condition is known, presenting the 
greatest challenge to finding effective treatment. It is possible 
that there is more than one cause with the same clinical mani-
festation, leading to different response rates to treatment. It 
is recognized in human medicine that response to treatment 
for neuropathic pain varies among individuals, even with the 
same diagnosis.32 Therefore, even if all trigeminal-mediated 
headshakers have the same underlying condition, response 
to the same treatment may vary.
To review the literature surrounding management strate-
gies, reliability of diagnosis, the mechanism of assessment 
of response used, and the placebo effect must be consid-
ered. Assessment of response to treatment can be challeng-
ing. Horses can vary from day to day and season to season 
in the severity of their signs and interpretation of these 
signs is heavily influenced by the placebo effect.18,23 The 
most objective measure currently available is classification 
of success as being return to ridden work at the previous 
level.22 Should data consistently demonstrate sensitization 
of the infraorbital in trigeminal-mediated headshakers, 
the next stage for research would be to determine whether 
the horses judged to have trigeminal-mediated headshak-
ing responded to treatment, and threshold potentials have 
returned to normal. This could allow measurement of 
threshold potentials before and after treatment to give an 
objective measure of response to treatment. However, the 
procedure requires general anesthesia which may limit its 
practical application.1
Diagnosis of trigeminal-mediated headshaking is cur-
rently made by exclusion, allowing potential for misdiagno-
sis. Some papers’ populations rely mostly on interpretation 
of clinical signs and even owner-led diagnosis. Again, further 
work demonstrating consistency of lowered infraorbital 
nerve threshold potentials could allow for this to be the gold 
standard for diagnosis but would always be limited by the 
requirement for general anesthesia. It would still be important 
to show there was no gross pathology leading to sensitization 
to complete a diagnosis.
There is a considerable placebo effect when interpreting 
results of treatments for headshaking.18,23 Where possible, 
trials of treatments for headshaking should include placebo 
or control group. However, this is not always possible due 
to welfare considerations in a group of horses suffering a 
painful condition.
This review will consider published treatments. 
There are many unpublished treatments used by owners 
of headshakers (Roberts et al 2018, unpublished data). 
Assessment of eff icacy of unpublished treatments is 
particularly challenging; it is not known if a veterinary 
diagnosis was made, or whether the criteria for success 
are sufficiently robust as to compensate for placebo effect 
of the owner. Without published data, they are not fur-
ther considered in this review. Published treatments are 
best considered in two categories: scientifically proved 
treatments and those with no effective results, even with 
apparent placebo effect.
The recent advances suggesting possibly reversible 
sensitization, may give opportunity for advance in therapy, 
although these remain limited and early in their inception. 
The rationale behind more established therapies with some 
evidence of success appears to reduce sensory input from the 
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trigeminal nerve, intended or not, even before sensitization 
was shown to occur.
Scientifically proven treatments
Nose net
This, shown in Figure 1, is the first treatment to try as it is 
cheap, noninvasive, risk-free, and is allowed in most competi-
tion at most levels. It is reported to give up to 70% relief in 
25% cases.6 The mechanism by which a nose net may work 
is likely to be similar to (but not the same as it does not travel 
through the spinal cord) gate control theory. This treatment 
is noninvasive, affordable, and accepted in most by many, 
but not all, competition regulatory bodies.
Pharmaceuticals
There are drugs available for the treatment of neuropathic 
pain in people and some of these have been used in trigem-
inal-mediated headshakers to see if their neuropathic pain 
could be managed this way. Even in people with neuro-
pathic pain, these drugs have inconsistent results and may 
confer side effects including drowsiness. A challenge to 
the efficacy of neuropathic pain is the heterogeneity of the 
mechanisms of neuropathic pain, and therefore heterogene-
ity is the best way to target its treatment.24 Of first-line drugs 
used for neuropathic pain in people, use of gabapentin has 
been published in the horse25 but not in cases of trigeminal-
mediated headshaking, although it is trialed in some cases 
(personal observation). Gabapentin is an anti-convulsant 
acting at calcium channels, which are expressed in the spinal 
cord, and it is this which gives them its analgesic properties; 
indeed, the number of voltage-gated calcium channels can 
increase in cases of neuropathic pain.24 Pharmacology and 
therefore dosing regimen of neuropathic pain pharmaceu-
ticals in the horse is often uncertain, although there is work 
on gabapentin (Dirikolu et al, 2007).35 Carbemazepine, a 
sodium-channel blocking anticonvulsant, can be effective 
to treat some cases of trigeminal neuralgia in people.20 
Mechanism of action is again to reduce central nerve con-
duction. Not all sufferers respond, some respond only for a 
short-term but even a short-term response can aid diagnosis, 
and some experience side effects.20 The use of carbam-
azepine alone, or in combination with cyproheptadine, a 
centrally acting antihistamine and serotonin antagonist 
(serotonin plays a role in pain sensation), is published in 
trigeminal-mediated headshakers.5,6 Results are mixed, and 
as with people, occasionally a positive response is merely 
short-term. Some horses may be affected by drowsiness, 
so there may be a need to consider whether they are safe to 
ride/handle. It is the author’s interpretation of these results 
that, as some individuals can respond well, these drugs 
can be worth trying as long as expectations are managed. 
It should be noted that use of these medications would not 
be allowed in competition, and this fact may be sufficient 
to limit further research in this area.
Homeopathy
About 93.3% owners felt their horses improved following 
homeopathic treatment of varying regimes, as part of a larger 
study into homeopathy.26
Sodium cromoglycate eye drops
Stalin et al27 published a short communication where 
administration of sodium cromoglycate (a mast cell stabi-
lizer) eye drops was effective in three seasonally affected 
horses, returning them to ridden exercise. This could sug-
gest allergic conjunctivitis as an etiology. Unfortunately, 
it appears that conventional allergy is not the cause in the 
majority of headshaking cases and the author has been 
unable to replicate these results, although trialing treat-
ment is low risk.Figure 1 Horse wearing a nose net.






Bilateral infraorbital neurectomy16 was effective in 3 out of 
19 horses with serious side effects being common; however, 
it was important in that it added to the weight of evidence of 
involvement of the trigeminal nerve.
Caudal ablation of the infraorbital nerve via coil compres-
sion had better results,28,29 with about a 50% success rate in 
57 horses but 26% relapsed with a median time of 9 months 
(range 2 months to 5 years). Most horses developed side 
effects of nose rubbing which were short-term in most cases 
but 4 out of 58 were euthanized due to severity or nonresolu-
tion of these side effects.
equiPeNS™ neuromodulation
This technique, demonstrated in Figure 2, was translated from 
percutaneous electrical nerve stimulation neuromodulation, 
a minimally invasive procedure which can have efficacy for 
the management of neuropathic pain in people. Potentially, 
the procedure is effective by normalizing neural function, 
but no basic science has been performed to investigate the 
mechanism of action. An initial trial, using an electrical 
protocol based on humans and an initial three procedure 
course, was published in 2016.22 This demonstrated that the 
procedure was possible to perform understanding sedation, 
had minimal risk of side effects, and returned five of seven 
horses to ridden work. More recent unpublished data on 168 
trigeminal-mediated headshakers receiving EquiPENS™ 
neuromodulation (530 procedures) have followed this work. 
The complication rate was 8.8% of procedures. In all but 
one case, complications were mild and transient, with no 
self-trauma. Remission of headshaking following the initial 
course occurred in 53% (72 out of 136) of horses. Median 
length of time recorded in remission was 9.5 weeks (range 
2 days to 156 weeks ongoing). Where signs recurred, most 
horses went back into remission following future procedures 
usually for longer time than the previous procedure. No 
predictors for outcome were determined. Should these data 
be published, it may suggest that EquiPENS™ neuromodula-
tion, while clearly carrying limitations, is a good first-line 
treatment for horses which do not respond to a nose net. 
Refinement of this procedure will remain limited not only 
until we understand the etiopathogenesis of trigeminal-
mediated headshaking but also the mechanism of action of 
neuromodulation, about which only little is currently known.
electroacupuncture
Electroacupuncture was attempted for the treatment of 
trigeminal-mediated headshaking, following the initial indi-
cation of possible success of EquiPENS™ neuromodulation 
and resulted in success in a small group of cases.21 As we do 
not understand the mechanism of action of neuromodulation 
or electroacupuncture, the only way to make a comparison 
is to compare the use of a uniform electroacupuncture tech-
nique to EquiPENS™ over a similar number of appropriately 
diagnosed horses.
Treatments with no effective results
Feed supplement
Talbot et al18 published a double-blinded placebo controlled 
trial of a commercial herbal feed supplement, marketed for 
treatment of headshaking. There was no real effect of the 
supplement or the placebo as judged by vets, but there was 
significant placebo effect of both the supplement and the 
placebo to the owner, who “felt their horses were improved”. 
This demonstrates the importance of using as objective a 
measure of success as is possible.
Gonadotropin-releasing hormone vaccine23
The use of this vaccine was investigated as the condition 
may be more common in geldings. In a study of 15 horses, Figure 2 Horse undergoing equiPeNS™ neuromodulation.
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there was no actual improvement as judged by vets but again 
one-third of owners felt their horses improved. Vaccination 
reactions were reported in 4 out of 15 cases.
Pulsed high-dose dexamethasone
Consistent with the above statement that conventional allergy 
is not a common cause of trigeminal-mediated headshak-
ing, pulsed high-dose dexamethasone was not effective for 
treatment.30
Various other treatments
Madigan and Bell5 performed a survey of owners of head-
shaking horses. While limited by owner-reported diagnosis 
and outcomes, with success of treatment judged by owner 
impression of improvement, no treatment – antihistamines, 
antimicrobials, corticosteroids, NSAIDs, melatonin, chiro-
practic treatment, acupuncture – stood out as more successful.
Conclusion
Trigeminal-mediated headshaking in horses is a condition 
with both welfare and economic implications. Further 
research is required to fully demonstrate proportions of 
horses affected worldwide and proportions of horses of 
each degree of severity, which would best indicate overall 
welfare and economic impact. There is also an absence of 
longitudinal data which would reveal whether and how the 
condition may be expected to progress and in what fashion, 
as well as the proportion of horses which may be expected 
to experience spontaneous resolution. Without this informa-
tion, the detailed full scale of the problem to the population 
is unknown.
Even in the absence of this information, impact of the 
individual horse and horse owner can be severe, even result-
ing in the euthanasia of the horse and all that implies to the 
owner. There is no one safe and effective treatment and even if 
aiming for management rather than cure, results are variable. 
While there are advances being made in understanding the 
condition and in progressing new treatments, major progress 
is unlikely until the etiopathogenesis is fully understood. In 
the meantime, the author recommends a thorough investiga-
tion to be as sure as possible of diagnosis, followed by logical 
trials of published treatments. Where horses are affected at 
rest and do not respond to treatment, euthanasia may be the 
only humane option.
Acknowledgments
The University of Bristol receives a fee, in majority for use 
to fund headshaking research, from training other centers in 
the use of EquiPENS™.
Disclosure
The author reports no conflicts of interest in this work.
References
 1. Pickles K, Madigan J, Aleman M. Idiopathic headshaking: is it still 
idiopathic? Vet J. 2014;201(1):21–30.
 2. Lane JG, Mair TS. Observations on headshaking in the horse. Equine 
Vet J. 1987;19(4):331–336.
 3. Moore LA, Johnson PJ, Messer NT, Kline KL, Crump LM, Knibb JR. 
Management of headshaking in three horses by treatment for protozoal 
myeloencephalitis. Vet Rec. 1997;141(11):264–267.
 4. Fiske-Jackson AR, Pollock PJ, Witte TH, Woolford L, Perkins JD. Fun-
gal sinusitis resulting in suspected trigeminal neuropathy as a cause of 
headshaking in five horses. Equine Vet Educ. 2012;24(3):126–133.
 5. Madigan JE, Bell SA. Owner survey of headshaking in horses. J Am 
Vet Med Assoc. 2001;219(3):334–337.
 6. Newton SA, Knottenbelt DC, Eldridge PR. Headshaking in horses: 
possible aetiopathogenesis suggested by the results of diagnostic 
tests and several treatment regimes used in 20 cases. Equine Vet J. 
2000;32(3):208–216.
 7. Mills DS, Cook S, Taylor K, Jones B. Analysis of the variations in 
clinical signs shown by 254 cases of equine headshaking. Vet Rec. 
2002;150(8):236–240.
 8. Williams WL. Involuntary twitching of the head relieved by trifacial 
neurectomy. J Comp Med Vet Arch. 1897;18:426–428.
 9. Williams WL. Involuntary shaking of the head and its treatment by 
trifacial neurectomy. Am Vet Rev. 1899;23:321–326.
 10. Aleman M, Williams DC, Brosnan RJ, et al. Sensory nerve conduction 
and somatosensory evoked potentials of the trigeminal nerve in horses 
with idiopathic headshaking. J Vet Intern Med. 2013;27(6):1571–1580.
 11. Aleman M, Rhodes D, Williams DC, Guedes A, Madigan JE. Sensory 
evoked potentials of the trigeminal nerve for the diagnosis of idiopathic 
headshaking in a horse. J Vet Intern Med. 2014;28(1):250–253.
 12. Aleman M, Pickles KJ, Simonek G, Madigan JE. Latent equine her-
pesvirus-1 in trigeminal ganglia and equine idiopathic headshaking. J 
Vet Intern Med. 2012;26(1):192–194.
 13. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogen-
esis. Brain. 2001;124(Pt 12):2347–2360.
 14. Roberts VL, Fews D, McNamara JM, Love S. Trigeminal nerve root 
demyelination not seen in six horses diagnosed with trigeminal-mediated 
headshaking. Front Vet Sci. 2017;15(4):72.
 15. Ross SE, Murray JK, Roberts VLH. Prevalence of headshaking within 
the equine population in the UK. Equine Vet J. 2018;50(1):73–78.
 16. Mair TS. Assessment of bilateral infra-orbital nerve blockade and 
bilateral infra-orbital neurectomy in the investigation and treatment of 
idiopathic headshaking. Equine Vet J. 1999;31(3):262–264.
 17. Dermanovic Dobrota V, Hrabac P, Skegro D, et al. The impact of neu-
ropathic pain and other comorbidities on the quality of life in patients 
with diabetes. Health Qual Life Outcomes. 2014;12:171.
 18. Talbot WA, Pinchbeck GL, Knottenbelt DC, Graham H, McKane SA. 
A randomised, blinded, crossover study to assess the efficacy of a feed 
supplement in alleviating the clinical signs of headshaking in 32 horses. 
Equine Vet J. 2013;45(3):293–297.
 19. Roberts V. Idiopathic headshaking: is it still idiopathic? Vet J. 
2014;201(1):7–8.
 20. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ Clin Evid. 
2014;2014:1207.
 21. Devereux S. Electroacupuncture as an additional treatment for head-
shaking in six horses. Equine Vet Educ. 2017;27:1–10
 22. Roberts VL, Patel NK, Tremaine WH. Neuromodulation using percu-
taneous electrical nerve stimulation for the management of trigeminal-
mediated headshaking: a safe procedure resulting in medium-term 
remission in five of seven horses. Equine Vet J. 2016;48(2):201–204.
 23. Pickles KJ, Berger J, Davies R, Roser J, Madigan JE. Use of a gonad-
otrophin-releasing hormone vaccine in headshaking horses. Vet Rec. 
2011;168(1):19.
Veterinary Medicine: Research and Reports 2019:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Veterinary Medicine: Research and Reports
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/veterinary-medicine-research-and-reports-journal
Veterinary Medicine: Research and Reports is an international, 
peer-reviewed, open access journal publishing original research, 
case reports, editorials, reviews and commentaries on all areas of 
veterinary medicine. The manuscript management system is com-
pletely online and includes a very quick and fair peer-review system. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 




 24. Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 
2017;6(Suppl 1):25–33.
 25. Davis JL, Posner LP, Elce Y. Gabapentin for the treatment of neuropathic 
pain in a pregnant horse. J Am Vet Med Assoc. 2007;231(5):755–758.
 26. Mathie RT, Baitson ES, Hansen L, Elliott MF, Hoare J. Homeopathic 
prescribing for chronic conditions in equine veterinary practice in the 
UK. Vet Rec. 2010;166(8):234–237.
 27. Stalin CE, Boydell IP, Pike RE. Treatment of seasonal headshak-
ing in three horses with sodium cromoglycate eye drops. Vet Rec. 
2008;163(10):305–306.
 28. Roberts VL, McKane SA, Williams A, Knottenbelt DC. Caudal 
compression of the infraorbital nerve: a novel surgical technique for 
treatment of idiopathic headshaking and assessment of its efficacy in 
24 horses. Equine Vet J. 2009;41(2):165–170.
 29. Roberts VLH, Perkins JD, Skärlina E, et al. Caudal anaesthesia of the 
infraorbital nerve for diagnosis of idiopathic headshaking and caudal 
compression of the infraorbital nerve for its treatment, in 58 horses. 
Equine Vet J. 2013;45(1):107–110.
 30. Tomlinson JE, Neff P, Boston RC, Aceto H, Nolen-Walston RD. 
Treatment of idiopathic headshaking in horses with pulsed high-dose 
dexamethasone. J Vet Intern Med. 2013;27(6):1551–1554.
 31. British Equestrian Trade Association. National Equestrian Survey; 2015. 
Available from: http://www.beta-uk.org/pages/industry-information/
market-information.php. Accessed November 30, 2018.
 32. Neuropathic pain in adults: pharmacological management in non-
specialist settings Clinical guideline [CG173]; 2013. Available from: 
https://www.nice.org.uk/guidance/cg173/chapter/1-Recommendations. 
Accessed April, 2018.
 33. Slater J. National equine health survey; 2013. Available from: http://
www.bluecross.org.uk/80135/national-equine-health-survey-html. 
Accessed November 30, 2018.
 34. World Health Organisation. Guide to identifying the economic conse-
quences of disease and injury; 2018. Available from: http://www.who.
int/choice/publications/d_economic_impact_guide.pdf?ua=1. Accessed 
November 30, 2018.
 35. Dirikolu L, Dafalla A, Ely KJ, Connerly AL, Jones CN, ElkHoly H, 
Lehner AF, Thompson K, Tobin T. Pharmacokinetics of gabapentin in 
horses. J Vet Pharmacol Ther. 2008;31(2):175–7.
